FDA’s ongoing efforts to ramp up its focus on drug safety are being borne out at the advisory committee level, which saw a doubling in the number of meeting days for the Drug Safety and Risk Management Advisory Committee in 2010.

Stéphane Bancel also gave conflicting answers for how the company set the cost of its mRNA COVID-19 vaccine as Democratic lawmakers tried to berate Moderna for its coming price hikes. Republicans lawmakers argue against retroactive shaming, saying that if the government wanted to set the eventual commercial price, it should have done that early in negotiations.